Mobile website
Archive > Volume 22 Issue 6 > 2015,22(6):740-746. DOI:10.3872/j.issn.1007-385X.2015.06.011 Prev Next
Clinical Research
Study on molecular diagnostic markers of differentiated thyroid tumors
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To identify molecular markers for accurate diagnosis of thyroid cancer the molecular phenotypes of varied proteiumark were evaluated in differentiated thyroid cancer (DTC) and benign thyroid lesions. Methods：Tissue microarrays containing 100 benign and 99 malignant thyroid lesions were stained for a panel of 57 molecular markers. Correlation between the marker staining and tumor pathology (DTC versus benign tumor) were determined using contingency table and Mann-Whitney U (MU) tests. A Random Forests classifier algorithm was also utilized to identify meaningful important molecular classifiers. Results： Of the 57 diagnostic markers evaluated, 35 (61%) were significantly associated with a DTC diagnosis after multiple testing correction. Among them, 8 markers were downregulated and 27 ones upregulated in DTC, when compared with benign thyroid tumor. The most significant markers for DTC diagnosis were Galectin-3, Cytokeratin 19, Vascular Endothelial Growth Factor, Androgen Receptor, p16, Aurora-A, and HBME-1. Using the entire molecular marker panel, a Random Forests algorithm was able to classify a neoplasm as DTC or benign tumor with an estimated sensitivity of 87.9%, specificity of 94.0%, and accuracy of 91.0%. Conclusion：Evaluating the DTC and benign thyroid tumor molecular phenotypes has allowed us to identify a diagnostic marker panel, which may help differentiate DTC with benign tumors and improve patient selection for thyroid surgery.
Keywords:
Project Supported:
Clc Number:
